Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease

Trial Profile

Phase 3 Prospective, Multicenter, Double-blind, Randomized, Active Control Study to Demonstrate Safety & Effectiveness of Neutrolin in Preventing Catheter-related Bloodstream Infection in Subjects on Hemodialysis for End Stage Renal Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Citrate/heparin/taurolidine (Primary)
  • Indications Bacterial infections; Catheter infections; Catheter thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms LOCK-IT-100
  • Sponsors CorMedix
  • Most Recent Events

    • 19 Mar 2018 According to a CorMedix media release, interim efficacy analysis of this study is anticipated to be completed in the second quarter of 2018. Company expects to complete the enrollment in the second quarter of 2018. Patients enrollment in this study is ongoing and till now, company enrolled 750 patients.
    • 26 Oct 2017 According to a CorMedix media release, data from this trial will be discussed at the worlds premier nephrology meeting, the American Society for Nephrologys Kidney Week.
    • 26 Oct 2017 According to a CorMedix media release, the company is planning an interim efficacy analysis of this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top